tetralol has been researched along with Glioblastoma in 1 studies
*Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alza, L; Cantí, C; Herreros, J; Visa, A | 1 |
1 other study(ies) available for tetralol and Glioblastoma
| Article | Year |
|---|---|
Tetralol derivative NNC-55-0396 induces glioblastoma cell death by activating IRE1α, JNK1 and calcium signaling.
Topics: Apoptosis; Benzimidazoles; Calcium; Calcium Signaling; Cell Death; Cyclopropanes; Endoplasmic Reticulum Stress; Endoribonucleases; Glioblastoma; Humans; Naphthalenes; Protein Serine-Threonine Kinases; Tetralones; Unfolded Protein Response | 2022 |